Literature DB >> 25541478

Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study.

Jonathan R Olsen1, John Gallacher2, Andrew Y Finlay3, Vincent Piguet3, Nick A Francis2.   

Abstract

BACKGROUND: Molluscum contagiosum is one of the 50 most prevalent diseases worldwide, but scarce epidemiological data exist for childhood molluscum contagiosum. We aimed to describe the time to resolution, transmission to household child contacts, and effect on quality of life of molluscum contagiosum in children in the UK.
METHODS: Between Jan 1, and Oct 31, 2013, we recruited 306 children with molluscum contagiosum aged between 4 and 15 years in the UK either by referral by general practitioner or self-referral (with diagnosis made by parents by use of the validated Molluscum Contagiosum Diagnostic Tool for Parents [MCDTP]). All participants were asked to complete a questionnaire at recruitment about participant characteristics, transmission, and quality of life. We measured quality of life with the Children's Dermatology Life Quality Index (CDLQI). Participants were prospectively followed up every month to check on their recovery from molluscum contagiosum and transmission to other children in the same household, until the child's lesions were no longer visible.
FINDINGS: The mean time to resolution was 13·3 months (SD 8·2). 80 (30%) of 269 cases had not resolved by 18 months; 36 (13%) had not resolved by 24 months. We recorded transmission to other children in the household in 102 (41%) of 250 cases. Molluscum contagiosum had a small effect on quality of life for most participants, although 33 (11%) of 301 participants had a very severe effect on quality of life (CDLQI score >13). A greater number of lesions was associated with a greater effect on quality of life (H=55·8, p<0·0001).
INTERPRETATION: One in ten children with molluscum contagiosum is likely to have a substantial effect on their quality of life and therefore treatment should be considered for some children, especially those with many lesions or who have been identified as having a severe effect on quality of life. Patients with molluscum contagiosum and their parents need to be given accurate information about the expected natural history of the disorder. Our data provide the most reliable estimates of the expected time to resolution so far and can be used to help set realistic expectations. FUNDING: Wales School of Primary Care Research (WSPCR) and Cardiff University.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25541478     DOI: 10.1016/S1473-3099(14)71053-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  7 in total

1. 

Authors:  Kayley Ogilvie-Turner; Ran D Goldman
Journal:  Can Fam Physician       Date:  2020-06       Impact factor: 3.275

Review 2.  New Developing Treatments for Molluscum Contagiosum.

Authors:  Francesco Lacarrubba; Giuseppe Micali; Andrea Calogero Trecarichi; Enrica Quattrocchi; Giuseppe Monfrecola; Anna Elisa Verzì
Journal:  Dermatol Ther (Heidelb)       Date:  2022-10-14

Review 3.  Interventions for cutaneous molluscum contagiosum.

Authors:  Johannes C van der Wouden; Renske van der Sande; Emma J Kruithof; Annet Sollie; Lisette Wa van Suijlekom-Smit; Sander Koning
Journal:  Cochrane Database Syst Rev       Date:  2017-05-17

4.  Cantharidin for molluscum contagiosum.

Authors:  Kayley Ogilvie-Turner; Ran D Goldman
Journal:  Can Fam Physician       Date:  2020-06       Impact factor: 3.275

5.  SB206, a Nitric Oxide-Releasing Topical Medication, Induces the Beginning of the End Sign and Molluscum Clearance.

Authors:  Tomoko Maeda-Chubachi; David Hebert; Elizabeth Messersmith; Elaine C Siegfried
Journal:  JID Innov       Date:  2021-05-05

6.  Molluscum contagiosum and associations with atopic eczema in children: a retrospective longitudinal study in primary care.

Authors:  Jonathan R Olsen; Vincent Piguet; John Gallacher; Nick A Francis
Journal:  Br J Gen Pract       Date:  2015-12-06       Impact factor: 5.386

7.  Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.

Authors:  Lawrence F Eichenfield; Wendy McFalda; Bradford Brabec; Elaine Siegfried; Pearl Kwong; Mark McBride; Jayson Rieger; Cynthia Willson; Matthew Davidson; Patrick Burnett
Journal:  JAMA Dermatol       Date:  2020-12-01       Impact factor: 10.282

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.